Bristol Myers Squibb (BMY) has been a subject of both positive and negative market movements recently. Moving in concert with the broader market, the company's stock has seen both slides and improvements, highlighting the importance of informed trading. With new institutional investors such as
InvesTrust and
Range Financial Group LLC buying into the company, BMY continues to attract significant investor attention. On a positive note, the company had its price target raised to $65.00 by
Truist Financial and achieved recognition by being named to the
Dow Jones Sustainability Index North America for the second consecutive year. Contributing to advancements in health, the
U.S. Food and Drug Administration (FDA) approved their injectable cancer drug
Opdivo, and a CAR T Cell Therapy for certain types of cancer. Remarkably, the company also managed to beat a $6.4 billion lawsuit regarding a delayed cancer drug. However, caution is advised due to the company’s predicted earnings decline.
Jim Cramer, the popular stock market commentator, noted the company's stock has been performing well since The Summer, and also spotlighted the potential game-changing impact of BMY's
Cobenfy, a new drug for schizophrenia.
Bristol-Myers Squibb BMY News Analytics from Fri, 05 Apr 2024 07:00:00 GMT to Fri, 10 Jan 2025 23:20:09 GMT -
Rating -1
- Innovation 5
- Information 8
- Rumor -2
